US2013336930A1PendingUtilityA1

Myxoma virus mutants for cancer treatment

54
Assignee: ROBARTS RES INSTPriority: Jun 1, 2006Filed: Aug 19, 2013Published: Dec 19, 2013
Est. expiryJun 1, 2026(expired)· nominal 20-yr term from priority
Inventors:John BarrettGrant Mcfadden
C12N 2710/24032A61K 35/768C12N 2710/24062A61P 35/00A61K 35/76C12N 7/00C12N 2710/24071A61K 39/275C12N 15/11
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for inhibiting a cancer cell comprising administering to the cell an effective amount of a Myxoma virus that is deficient in the activity of a Myxoma virus protein selected from the group consisting of MI 1L, M063, M136, M-T4 and M-T7. 
     
     
         2 . The method of  claim 1 , wherein the Myxoma virus has substantially no activity of the Myxoma virus protein selected from the group consisting of M1 IL, M063, M1 36, M-T4 and M-T7. 
     
     
         3 . The method of  claim 1 , wherein the cell is a mammalian cancer cell. 
     
     
         4 . The method of  claim 3 , wherein the cell is a human cancer cell. 
     
     
         5 . The method of  claim 4 , wherein the cell is a glioma cell. 
     
     
         6 . A method for treating a human subject having cancer, comprising administering to the patient an effective amount of a Myxoma virus that is deficient in the activity of a Myxoma virus protein selected from the group consisting of M1 IL, M063, M1 36, M-T4 and M-T7. 
     
     
         7 . The method of  claim 6 , wherein the Myxoma virus has substantially no activity of the Myxoma virus protein selected from the group consisting of MI 1L, M063, M1 36, M-T4 and M-T7. 
     
     
         8 . The method of  claim 6 , wherein the cancer is a glioma. 
     
     
         9 . A pharmaceutical composition comprising a Myxoma virus and a pharmaceutically acceptable carrier for use in treating cancer, wherein the Myxoma virus is deficient in the activity of a Myxoma virus protein selected from the group consisting of M1 IL, M063, M1 36, M-T4 and M-T7. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the Myxoma virus has substantially no activity of the Myxoma virus protein selected from the group consisting of M1 IL, M063, M136, M-T4 and M-T7. 
     
     
         11 . The pharmaceutical composition of  claim 9 , wherein the cancer is a glioma. 
     
     
         12 . A kit comprising a Myxoma virus and instructions for treating a patient having cancer, wherein the Myxoma virus is deficient in the activity of a Myxoma virus protein selected from the group consisting of MI 1L, M063, M1 36, M-T4 and M-T7. 
     
     
         13 . The kit of  claim 12 , wherein the Myxoma virus has substantially no activity of the Myxoma virus protein selected from the group consisting of M1 IL, M063, M136, M-T4 and M-T7.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.